WASHINGTON (dpa-AFX) - Seattle Genetics, Inc. (SGEN) announced updated survival data from a pivotal clinical trial of single-agent ADCETRIS (brentuximab vedotin) in patients with relapsed or refractory Hodgkin lymphoma, or HL, after autologous stem cell transplant, or ASCT. The updated survival data showed that the median overall survival has not been reached after a 26.5 month median follow-up.
According to the company, a pivotal trial was conducted in 102 patients with relapsed or refractory HL after ASCT. The primary endpoint was objective response rate per independent review. The secondary endpoints were complete remission rate, duration of response, progression-free survival, overall survival, and safety and tolerability.
'Heavily pretreated Hodgkin lymphoma patients who relapse following autologous stem cell transplant often have a poor prognosis and there is a high unmet medical need for effective treatment options,' said Scott Smith, Loyola University Medical Center. 'These updated overall survival results from the pivotal trial are encouraging and demonstrate that ADCETRIS may play an important role in the treatment of patients with relapsed or refractory disease.'
Copyright RTT News/dpa-AFX
